Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/146483
Title: | Ly9 (CD229) antibody targeting depletes marginal zone and germinal center B cells in lymphoid tissues and reduces salivary gland inflammation in a mouse model of Sjögren's Syndrome |
Author: | Puñet Ortiz, Joan Sáez Moya, Manuel Cuenca, Marta Caleiras, Eduardo Lázaro, Adriana Engel Rocamora, Pablo |
Keywords: | Autoimmunitat Síndrome de Sjögren Models animals en la investigació Autoimmunity Sjogren's syndrome Animal models in research |
Issue Date: | 16-Nov-2018 |
Publisher: | Frontiers Media |
Abstract: | Sjögren's Syndrome (SjS) is a common chronic autoimmune disease characterized by the B cell hyperactivation, lymphocyte infiltration, and tissue damage of exocrine glands. It can also present life-threatening extraglandular manifestations, such as pulmonary and hepatic involvement, renal inflammation and marginal zone (MZ) B cell lymphoma. Several biologic agents have been tested in SjS but none has shown significant efficacy. Here, we report the effects of Ly9 (CD229) antibody targeting, a cell surface molecule that belongs to the SLAM family of immunomodulatory receptors, using NOD.H-2h4 mice as a model of SjS-like disease. Female mice were treated with anti-Ly9 antibody or isotype control at week 24, when all mice present SjS related autoantibodies, salivary gland infiltrates, and marginal zone (MZ) B cell pool enlargement. Antibody injection depleted key lymphocyte subsets involved in SjS pathology such as MZ, B1, and germinal center B cells in spleen and draining lymph nodes without inducing a general immunosuppression. Importantly, mice receiving anti-Ly9 mAb showed a reduced lymphocyte infiltrate within salivary glands. This reduction may be, in part, explained by the down-regulation of L-selectin and alfa4/beta7 integrin induced by the anti-Ly9 antibody. Furthermore, levels of anti-nuclear autoantibodies were reduced after anti-Ly9 treatment. These data indicate that Ly9 is a potential therapeutic target for the treatment of SjS. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2018.02661 |
It is part of: | Frontiers in Immunology, 2018, vol. 9, p. 2661 |
URI: | http://hdl.handle.net/2445/146483 |
Related resource: | https://doi.org/10.3389/fimmu.2018.02661 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
686408.pdf | 5.17 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License